Updates and news related to prostate cancer:
Presented by Alan Hsu, MD Psychiatrist, UC San Diego Health, a board-certified psychiatrist specializing in treating cancer patients struggling with mood and anxiety issues brought on by cancer
What you need to know: tips and information to protect yourself and your family
Tips from the toolkit for oncology health care professionals
Seven takeaways from a community symposium highlighting recent advances in prevention, screening and treatment
Hormone therapies for advanced prostate cancer have greatly prolonged the lives of patients
Enzalutamide has previously been FDA-approved for treatment of metastatic castration-resistant prostate cancer (mCRCP) and non-metastatic castration-resistant prostate cancer (nmCRPC).
A new pilot study concludes that at-home urine tests could make prostate cancer diagnosis shorter, simpler, and possibly even more accurate.
After treatment, 65 percent of men in study had no signs of cancer after one year.
By Radiological Society of North America, December 2, 2019
The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the American Society of Clinical Oncology.